41
Views
0
CrossRef citations to date
0
Altmetric
Plain Language Summary of Publication

Measuring fatigue in people with multiple sclerosis – which questionnaire should be used? A Plain Language Summary of Publication

, , , , , , , & show all
Pages 5-9 | Received 22 Sep 2023, Accepted 28 Feb 2024, Published online: 29 Mar 2024

Plain Language Summary

This summary explains the findings of a recent study that compared different questionnaires used by doctors to measure levels of fatigue in people with multiple sclerosis (MS). The aim of the study was to find out which questionnaire doctors should use to measure fatigue in people with MS in the future.

Fatigue, which can be described as the overwhelming feeling of tiredness or exhaustion, is a very common symptom of MS. For the majority of people with MS, fatigue is one of the worst symptoms of MS, so it is essential that doctors can measure it accurately. Currently, people with MS are asked to complete questionnaires so that their care team can see the effect of fatigue on their day-to-day lives.

There are many questionnaires that are used to measure fatigue in people with MS. It would be valuable to come to an agreement, based on evidence from research like this study, on which questionnaire is the most appropriate for measuring fatigue in both research and healthcare settings.

This study compared a questionnaire called the PROMIS® Fatigue (MS) 8a, referred to throughout this summary as the PROMIS® MS Fatigue Short Form, with two of the most commonly used questionnaires: the Fatigue Severity Scale (FSS) and the Modified Fatigue Impact Scale (MFIS). The questionnaires were compared to see which one should be recommended to doctors for measuring fatigue in people with MS.

What are the key takeaways?

It was found that while all three questionnaires were good, the PROMIS® MS Fatigue Short Form questionnaire was better than the other two questionnaires at showing differences in levels of fatigue between people with MS. The PROMIS® MS Fatigue Short Form was also found to be better than the Fatigue Severity Scale (FSS) at showing changes in the person with MS’s level of fatigue. The PROMIS® MS Fatigue Short Form questionnaire may help people with MS to better communicate challenges with their fatigue to their doctors.

What was the main conclusion reported by the researchers?

The study suggests that the PROMIS® MS Fatigue Short Form questionnaire is a helpful tool for doctors and people with MS to measure fatigue.

Plain Language Summary

Which questionnaire should doctors be using to measure levels of fatigue in patients with #MultipleSclerosis? Take a look at this plain language summary of a recent study from P Kamudoni et al. (#MerckHealthcareKGaA), to find out.

This is an abstract of the Plain Language Summary of Publication article.

To read the full Plain Language Summary of this article, click here to view the PDF .

Link to original article here

Acknowledgments

We would like to acknowledge the following people with MS as expert reviewers on this plain language summary of publication: Gus Alexiou, Grainne Rouleau and Janina Woznicka. The original authors reviewed and approved the final content of this summary: Dr. Paul Kamudoni, Dr. Jeffrey Johns, Dr. Karon F Cook, Dr. Rana Salem, Prof. Sam Salek, Jana Raab, Dr. Rod Middleton, Christian Henke and Dr. Dagmar Amtmann.

Financial disclosure

This summary was funded by Merck KGaA, Darmstadt, Germany.

Competing interests disclosure

Paul Kamudoni, Christian Henke and Jana Raab are employees of the Merck Healthcare KGaA, Darmstadt, Germany. Karon Cook has provided consultancy to Merck Healthcare KGaA, Darmstadt, Germany. Sam Salek has a consultancy contract with Merck Healthcare KGaA, Darmstadt, Germany and unrestricted educational grants from GSK and the European Haematology Association. Dagmar Amtmann has received research funding from EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Darmstadt, Germany. Rana Salem has received research funding from EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Darmstadt, Germany. Jeffrey Johns and Rod Middleton have nothing to disclose. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing disclosure

Emily Martin-Vazquez, of Lumanity, provided writing, editorial support and formatting assistance, which was contracted and funded by Merck KGaA, Darmstadt, Germany.

Open access

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/